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doi:10.1016/j.jtcvs.2006.02.022bjective: The use of tissue glues has been advocated to reduce post-thoracotomy
lveolar air leaks, but outcomes have been inconclusive. The aim of this study was
o determine the effectiveness of BioGlue (CryoLife Europa Ltd, Hampshire, United
ingdom) in eliminating post-thoracotomy alveolar air leaks.
ethods: A prospective, randomized, single-blind, controlled trial was conducted in
hich patients were stratified according to the severity of post-thoracotomy air leak
hat could not be controlled by conventional surgical techniques. They were allo-
ated to a control arm (surgical treatment only) or an interventional arm (surgical
reatment and BioGlue). Duration of air leak, intercostal drainage, and hospital stay
omprised primary study end points.
esults: From December 2002 to January 2005, 52 patients were randomized, 29
56%) of whom were men. The mean age was 59  15 years, and other character-
stics were comparable in both groups. Indications for surgery were malignancy in
6 patients (88%), carcinoid tumor in 2 patients (4%), and infective disease in 4
atients (8%). Patients in the BioGlue arm had shorter median duration of air leaks,
(0-2) versus 4 (2-6) days (P  .001); intercostal chest drainage, 4 (3-4) versus 5
4-6) days (P  .012); and hospital stay, 6 (5-7) versus 7 (7-10) days (P  .004),
ompared with controls. No major complications were encountered using BioGlue.
onclusions: This study demonstrates clear benefit from BioGlue in the treatment of
lveolar air leaks through reduction of air leak duration, chest drainage time, and
ospital stay. Systematic use of BioGlue may be warranted in adult thoracic surgical
rocedures (except pneumonectomy and decortication) when an air leak remains
fter all other steps to control it have failed.
rolonged alveolar air leak (AAL) after thoracotomy is generally defined as an
air leak that lasts more than 7 days. AAL prevalence is greater than 15%, and
it may result in serious complications including longer duration of intercostal
rainage and increased immobility with associated risks of infection, empyema, and
hromboemboli.1-3 These complications may lead to greater postoperative pain 
onger hospital stays with increased associated costs.4
Various attempts have been made to prevent or reduce the incidence of post-
horacotomy AAL including additional surgical techniques, postoperative water-
eal drainage, and surgically applied sealants.5-12
Experimental use of fibrin glue initially showed promise in reducing AAL,13 but
ore recent clinical studies showed less benefit,14,15 and others were compromise
y nonrandomized methodology or routine use of glue irrespective of the presence
r degree of AAL,16-19 which may have diluted the effect of the sealan
opulating both the control and intervention groups with patients destined to do well
egardless of group assignment.
BioGlue (CryoLife Europa Ltd, Hampshire, United Kingdom) surgical adhesive
s a topically applied mixture of bovine serum albumin and glutaraldehyde. In North
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G
TSmerica, it is approved for use as an adjunct to standard
ethods of hemostasis in open surgical repair of large
essels.20,21 It also has European approval for use in a 
ange of soft tissue repairs.22
The aim of this trial was to determine the effectiveness of
ioGlue in eliminating post-thoracotomy AAL using clini-
ally relevant outcome measures.
aterials and Methods
ioGlue and Application
ioGlue surgical adhesive is a topically applied mixture of
ovine serum albumin and glutaraldehyde. It is supplied in a
refilled cartridge and stored below 25°C. The components of
he product are mixed within a double-helix applicator attached
o a syringe. Polymerization with tissues occurs immediately on
pplication, and bonding strength is reached within 2 minutes.
vidence of incomplete resorption of BioGlue has been iden-
ified at 2 years.23
articipants
his was a prospective, randomized, single-blind, controlled study
ith 3 participating consultant surgeons. Before the study was begun,
pproval was obtained from the Royal Brompton, Harefield, and
ational Heart Lung Institute Ethics Committee. Informed patient
onsent was obtained before each operation. The study was per-
ormed at the Royal Brompton Hospital during a 25-month period
December 2002 to January 2005). Inclusion criteria included adults
ged more than 18 years undergoing any thoracic surgical procedure
including redo surgery) likely to result in AAL, with the exception
f decortication for acute empyema because of the potential risk of
ioGlue acting as a foreign body, which may increase risk of
nfection as shown after the use of other lung sealants.11 Exclusion
riteria included age less than 18 years, pregnancy/breastfeeding,
revious ipsilateral treatment with BioGlue, no air leak at the end
f the surgical procedure, and pneumonectomy surgery.
andomization
andomization was undertaken with sequential closed envelopes
tratified by the severity of air leak in permuted blocks of 6. In
ach case, the operating surgeon decided on trial entry on the basis
f any grade of air leak that could not be controlled by conventional
urgical techniques comprising sutures and diathermy. Patients in
hom AAL could be controlled in this way were not included.
ntervention
fter completion of each surgical procedure, the thoracic cavity
as filled with warm water (malignant cases) or saline (benign
ases) to ensure that all dissected fissures, staples, suture lines, and
ulmonary parenchymal surfaces were immersed. The lung was
Abbreviations and Acronyms
AAL alveolar air leak
POD postoperative dayhen mechanically ventilated to inflate any atelectatic zones. An i
06 The Journal of Thoracic and Cardiovascular Surgery ● Julynd-inspiratory airway pressure of 25 cm water (2.5 kPa) was
pplied to assess the degree of air leak, which was graded 0 to 3
sing a simple, easily reproducible technique (Table 1).
Air leaks of grades 1 to 3 prompted a conventional surgical
ontrol attempt by sutures and diathermy as determined by the
perating surgeon. If AAL persisted after all appropriate mea-
ures had been taken, grade-dependent, closed-envelope ran-
omization was undertaken between the interventional arm
BioGlue) and non-interventional (surgical treatment only) con-
rol arm. Fluid was evacuated from the chest cavity. In the
nterventional arm, BioGlue was then applied to the deflated lung
o avoid any potential disruption of its structural integrity during
he bonding process as a result of air leak. The amount applied was
ept to the minimum considered appropriate by the operating
urgeon, but as many packs were used as required to ensure the
ung was airtight. It was directly squirted on with the product
pplicator by the consultant or a senior trainee under direct con-
ultant supervision. A 2-minute pause was then timed to allow the
ioGlue to reach bonding strength before the lung was reinflated,
nd assessment for air leaks was repeated until lung integrity was
nsured. No BioGlue was applied to bronchial stumps or sleeve
nastomoses.
All patients had 1 or 2 drains, as clinically appropriate, placed to
he apex (anteriorly and/or posteriorly, with basal holes cut in addi-
ion) before chest closure and were managed on an underwater-
ealed basis. Fifty of the 52 randomized cases were cared for by 2
urgeons who managed patients according to an identical postop-
rative chest drain protocol, and 1 patient in each arm was man-
ged by a surgeon who did not apply suction to the underwater
eal. The chest drain protocol involved the intraoperative applica-
ion of 5 kPa (51 cm water) negative pressure suction at the end of
ach case, continuing until any air leaks had stopped. It was then
onverted to an underwater seal only without suction for a period
f 24 hours. If no further air leaks were present, drains were then
emoved.
Postoperative air leaks were defined as the presence of a single
ubble of air in the chest drains during the course of normal or
orced expiration (coughing). Only senior trainees, with an agreed
efinition of postoperative air leak, performed daily objective
ssessments that were concurrently verified by independent senior
ursing staff. Chest drains were removed when no further bubbles
ere identified during daily assessment. Persistent air leaks after
4 days of standard intercostal chest drainage were converted to
eimlich valve drainage. For statistical analysis in these cases,
rolonged air leaks were considered present until removal of
ABLE 1. Intraoperative air leak grading
ir leak grading Intraoperative physiologic definition
0 No leak
1 Minor leak
2 Moderate leak not detected by anesthetist but
easily visible to surgeon
3 Major leak detected by anesthetist through
loss of ventilation volumentercostal chest drains.
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G
TStatistical Methods
he primary outcome measures were duration of air leak, inter-
ostal drain time, and hospital stay. Any observed complications
ere also carefully noted. Patients were grouped according to
reatment allocation and compared with t tests for normally dis-
ributed measures, Mann-Whitney tests for non-normally distrib-
ted measures, and Fisher exact test for proportions. In addition, a
ime-to-event Kaplan-Meier analysis was performed and compared
sing the Peto test.
ample Size Calculation
n the basis of a retrospective review of data obtained in the
horacic surgical department at the Royal Brompton Hospital, 62%
f patients were expected to have their chest drains removed on or
efore the third day. On this basis, our null hypothesis was that
here would be no difference in the proportion of patients achiev-
ng chest drain removal at postoperative day (POD) 3. With 90%
ower and a significance level of 5% to detect a difference of 20%,
t was calculated that 94 patients would be required to conduct the
tudy. Allowing for 10% dropout, we planned to recruit 104
atients (52 in each arm) in total. An interim analysis was planned
t halfway through the study after 52 patients had been recruited,
nd the trial would be stopped if conventional levels of statistical
ignificance were achieved.
esults
atients and Operations
uring the 25-month recruitment period, 210 patients con-
ented to be included in the study. Of these, 158 patients had
ABLE 2. Patient demographics
Control arm
(n  27)
BioGlue arm
(n  25) P value
ean age (y), n (SD) 60 (15) 59 (16) .670
ale sex, n (%) 15 (56) 14 (56) 1.000
eoperation, n (%) 2 (7) 3 (12) .662
rocedure, n (%)
Lobectomy 12 (44) 9 (36)
Lobectomy  lesser
resection
3 (11) 3 (12) .351
Segmentectomy 7 (26) 2 (8)
Lingulectomy 1 (4) 1 (4)
Metastasectomy 4 (15) 8 (32)
Other 0 2 (8)
iagnosis, n (%)
Malignancy (primary or
secondary)
26 (96) 20 (80)
Carcinoid 1 (4) 1 (4) .140
Infection 0 (0) 4 (16)
everity of air leak, n (%)
Mild 20 (74) 20 (80)
Moderate 5 (18) 5 (20) .640
Severe 2 (7) 0 (0)
D, Standard deviation.o intraoperative air leak at the end of the procedure after 1
The Journal of Thoraciconventional surgical control measures, and no patient re-
uired pneumonectomy. Fifty-two patients fulfilled intraop-
rative criteria appropriate for randomization (25 in the
ioGlue arm; 27 in the non-interventional arm). More than
pack of BioGlue was used in only 2 cases in the inter-
entional arm. Forty-two patients had 2 drains placed, and
0 patients had 1 drain placed. Demographics of each group
ere well matched; the small discrepancy in the numbers of
atients in each arm arose by chance because the trial was
topped midway through a randomization block for grade 3
ir leaks (Table 2).
rimary Outcome Measures
t the interim analysis conducted halfway through the study, a
horter median duration of air leak (P .001), intercostal chest
rainage (P  .012), and hospital stay (P  .004) were
dentified in favor of the BioGlue arm (Table 3; Figures
n addition, 10 of 27 patients (37%) in the control group and 19
f 25 patients (76%) in the BioGlue arm had the chest drain
emoved on or before POD 3. The difference was 39% in favor
f the BioGlue arm (P  .004). We decided to stop the trial
arly because of these results.
bserved Complications
total of 24 complications occurred in 17 patients. Five
atients (2 in the BioGlue arm and 3 in the control arm) had
rolonged AAL resulting in delayed removal of the inter-
ostal chest drains. The drain was converted to a Heimlich
ystem on POD 9 (outside the usual protocol on POD 14) in
patient (BioGlue arm) to allow safe transfer to a computed
omography scanner before eventual removal on POD 29;
he AAL in the other patient in the BioGlue arm settled on
OD 12, after which the drain was removed on POD 13.
he drains were removed on POD 12 5 (mean standard
eviation) in 3 patients in the control arm despite the con-
inued presence of air leaks, which were not considered to
e of clinical importance. No patients required subsequent
einsertion of drains.
Two patients in the control arm required reintubation for
espiratory failure and readmission to the intensive care
nit; 1 patient recovered and was discharged on POD 9, and
ABLE 3. Primary outcomes
Control arm
(n  27)
BioGlue arm
(n  25) P value*
uration of air leak (d) 4 (2-6) 1 (0-2) .001
uration of intercostal
drainage (d)
5 (4-6) 4 (3-4) .012
uration of hospital stay (d) 7 (7-10) 6 (5-7) .004
ll numbers presented as median with interquartile range. *P values
btained using Mann-Whitney test.patient had multiorgan failure and died on POD 16.
and Cardiovascular Surgery ● Volume 132, Number 1 107
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1
G
TSOther more minor complications resulting in delayed
ischarge included diarrhea in 3 patients (1 in the BioGlue
rm; 2 in the control arm); nonsignificant arrhythmias in 2
atients (control arm); bowel complications requiring con-
ervative management in 2 patients (control arm); difficult
nalgesic management in 2 patients (control arm); clinically
nimportant pneumothoraces after the initial intercostal
hest drain removal in 2 patients (1 apical and 1 basal; both
n the BioGlue arm) requiring conservative management
nly; pneumothorax requiring further intercostal drain in-
ertion in 1 patient (BioGlue arm); prolonged fluid drainage
or no obvious reason in 1 patient (control arm), which delayed
ntercostal drain removal by 3 days; and prolonged fluid drain-
ge in 2 patients (BioGlue arm), one for no identifiable reason
ut it required 4 extra days of chest drainage, and one
oninfected chylous leak caused by a thoracic duct injury
hat required closure at redo-thoracotomy, resulting in de-
ayed intercostal drain removal by 6 extra days.
iscussion
iologic glues are not an alternative to meticulous surgery.
owever, there has been much recent investigation into
heir value as adjunctive therapy for patients with difficult
ir leaks at surgery that do not respond to conventional
urgical techniques. Unfortunately, some studies using a
ariety of glues have lacked rigorous scientific method and
ave enrolled heterogeneous groups of patients, thus pro-
ucing results and conclusions from which little can be
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08 The Journal of Thoracic and Cardiovascular Surgery ● JulyAt the time this study was designed, the 4 prospective,
andomized, controlled trials that compared standard clo-
ure techniques plus sealant with standard closure tech-
iques alone in elective lung resection (mainly for lung
ancer) published conflicting results regarding treatment
ffectiveness for postoperative AAL.24 Two of the tria
sing fibrin glue showed no statistical differences between
reatment and controls when comparing reduction of dura-
ion of AAL, intercostal drainage, and length of hospital-
zation.14,15 However, the other 2 trials, 1 of which 
brin glue and 1 of which used a novel synthetic hydrogel
ealant (FocalSeal, Focal Inc, Lexington, Mass), showed a
ignificant reduction in postoperative AAL in the treatment
roups but no differences in hospital stay, intercostal chest
rainage, or other complications.25,26 Despite the conclu-
ion that surgical sealants may offer some benefit in reduc-
ng postoperative AAL, the non-uniformity of evidence
eant that their systematic clinical use could not be advo-
ated and that further randomized, controlled trials were
ecommended.24
A more recent review examined 8 similar trials.27 Of the
2 trials thus examined in total, 9 showed a statistically
ignificant difference between treatment and control groups
n reducing postoperative AAL.17,25,26,28 –33 However, in
nly 1 trial each did this lead to a significant reduction in
uration of intercostal chest drainage17 or hospital stay.28
he authors concluded that although surgical sealants
eemed to reduce the duration of postoperative AAL, dura-
9 10 11 12
Control
BioGlue
P<0.001
3 2 2 2
2 2 2 2
Figure 1. Percentage probability
of air leak after surgery. Intraop-
erative randomization at time
point zero. Subsequent assess-
ment in the recovery room
shown adjacent to time point
zero. Number of patients at risk
at any time are shown above the
x-axis.8
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2ion of intercostal chest drainage and hospitalization was
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G
TSargely unaffected. As a result of these inconclusive results
rom heterogeneous trials using a variety of sealants, it was
gain concluded that their systematic use could not be
ecommended and that further randomized control trials are
eeded.27
Until now, BioGlue has only been subjected to retrospec-
ive, nonrandomized, uncontrolled studies on heterogeneous
roups of patients to examine its effectiveness in reducing
AL.34-36 Therefore, its use remains largely determined 
ndividual surgeon preference. The aim of this study was to
xamine the management of AAL, of all degrees of severity,
sing BioGlue in a prospective, randomized, controlled
anner, in a clinically relevant scenario in which an air leak
ersists after all conventional techniques have been ex-
austed. Inclusion criteria were deliberately broad in an
ttempt to reflect the practice of a typical thoracic surgical
nit so results would be clinically relevant and widely
pplicable. Almost all patients underwent resection of pul-
onary tissue to some degree (Table 2). The intraoper
ir leak grading system was simple, pragmatic, and easily
eproducible. It worked well and allowed easy inter-surgeon
ommunication. A carefully stratified randomization pro-
ess ensured that patients were well matched for the initial
everity of air leak. It was not possible to measure the
olume of glue applied to each leak, given the design of the
pplicator devices, and the urgent priority required for ac-
urate surgical placement of glue, given the rapidity of
onding after application. However, the volume applied was
ept to the minimum considered appropriate by each oper-
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25 25 24 20 13 6 4 3 3 3ting surgeon to ensure the lung was airtight. In only 2 cases o
The Journal of Thoracicith multiple air leaks was more than 1 pack used, but again
he minimum possible was applied to each individual leak.
lthough this area may constitute a limitation of the trial,
ariation was minimized as much as possible within prac-
ical limitations.
The number of drains inserted was dictated by the clin-
cal need as assessed by the operating consultant surgeon.
e did not believe it was ethical to impose any other
egimen. Although we recognize this is a potential limita-
ion of the trial, we do not believe it affected the results,
ecause air leak presence was defined as a single bubble of
ir that should be identifiable irrespective of the number of
rains placed. In addition, the shorter duration of air leak in
he treatment arm is statistically independent of any differ-
nce in chest drain management.
In total, 50 of the 52 randomized cases were cared for by
surgeons who managed patients according to an identical
ostoperative chest drain protocol, and 1 patient in each arm
as managed by a surgeon who did not apply suction to the
nderwater seal. The chest drain protocol involved the in-
raoperative application of 5 kPa (51 cm water) negative
ressure suction at the end of each case, continuing until any
ir leaks had stopped. It was then converted to an under-
ater seal only, without suction, for a period of 24 hours.
f no further air leaks were present, the drains were then
emoved. In this context we do not believe that there was
ny significant difference in postoperative chest drain man-
gement that would impair the results of the study. More-
11 12 13 14 15
Control
BioGlue
=0.010
3 2 2 2 1
3 3 2 1 1
Figure 2. Percentage probability
of continued requirement for in-
tercostal chest drainage after
surgery. Recovery room assess-
ment at time point zero. Number
of patients at risk at any time are
shown above the x-axis.10
P
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3ver, “time to resolution of air leak,” which was statistically
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G
TSignificant, is independent of any differences in chest drain
anagement.
The results clearly demonstrated advantage in the intra-
perative use of BioGlue in reducing AAL, duration of inter-
ostal chest drainage, and in-hospital stay after thoracotomy.
ll of these primary outcome measures demonstrated statis-
ical significance consistently in favor of BioGlue. Figu
emonstrates that the beneficial effects of BioGlue occurred
rom the time of intraoperative administration because there
as a greater incidence of patients leaving the operating
oom, compared with controls, without an air leak. In ad-
ition, air leaks then settled much more quickly in the
ioGlue arm in comparison with the slower, steadier pace
een in controls. The translated clinical benefits were a
horter duration of intercostal chest drain requirement and
ospital stay by 1 day each. In contrast, it can also be clearly
een in Figure 1 that almost all patients not rece
ioGlue had an air leak on leaving the operating room, and
n 68% it was still present on POD 2. Although these results
re not characteristic of our unit’s practice, they may reflect
he fact that for the purposes of the study, a single air bubble
as considered to represent an “air leak.” In regard to the
elevant complications, 2 of the 3 pneumothoraces noted in
he BioGlue arm after chest drain removal were small,
linically unimportant, and did not require treatment. A
hird required further drainage with successful outcome. We
re unable to determine conclusively whether they occurred
urely by chance. Certainly there was no statistically sig-
ificant difference (Fisher exact test, P .10); however, the
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Time from surgery in daysumber of complications are small, and we would regard e
10 The Journal of Thoracic and Cardiovascular Surgery ● Julyur observation of 3 recurrent pneumothoraces with appro-
riate caution. Possible bias toward earlier removal of
rains in the treated group was minimized, because deci-
ions were still governed on the basis of air leak, which was
uicker to resolve in the BioGlue arm.
Prolonged daily fluid outputs occurred in 3 patients (2 in
he BioGlue arm; 1 in the control arm), all of whom under-
ent resection for malignancy. This did not affect statistical
nalysis for duration of air leaks measured independently,
nd despite the required extra duration of chest drainage in
he patients in the BioGlue arm, time to overall removal of
hest drains was still statistically significantly shorter in the
ioGlue arm.
Small sample size, calculated for the original study to
nclude 104 patients, may be a limitation of the trial. How-
ver, the trial was stopped at its halfway point, on the basis
f interim analysis of results, because the predefined end
oints had been reached. Although the numbers may seem
mall, appropriate considerations were taken into account
or power and sample size calculation.
The greater effect size identified in comparison with
revious trials prompts the question of whether it relates to
he product itself or alternatively to the exclusion of patients
ithout air leaks at the end of the operation. This remains a
ifficult question to answer. Certainly the methodology of
his trial sought to assess the product’s effectiveness only in
atients who had an air leak that was not controllable by
onventional measures. This differed from some other trials
n which lung sealants were applied irrespective of the pres-
15 16 17 18 19 20 21
4 4 3 3 2 1 1
3 2 1 1 1
Control
BioGlue
P=0.003
Figure 3. Percentage probability
of in-hospital stay after surgery.
Recovery room assessment at
time point zero. Number of pa-
tients at risk at any time are
shown above the x-axis.14
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3nce of air leak, an action that may have diluted the effect
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G
TSf the sealants examined by populating both the control and
ntervention groups with patients destined to do well regard-
ess of group assignment.17,19 The fact that our trial differ
n this regard may well have influenced the outcome and is
he key to differentiating this trial from others. However, the
roduct itself may also have conferred benefits not present
n other sealants. The contribution of each component is
ifficult to quantify, but the outcome is likely to relate to an
lement of both factors. Because the product was evaluated
n small groups in this trial, but in a methodologically
ppropriate manner, interpretation of the encouraging re-
ults in comparison with other trials should be left to the
eader, but further large-scale studies are encouraged to
xtend and confirm the data.
Some generic concerns remain regarding tissue glues,
ncluding the potential risk of bloodborne disease transmis-
ion. Although we are not aware of any specific incidences
ith BioGlue, its bovine product formulation must be con-
idered. In this respect, efficacious autologous fibrin prep-
rations might confer advantage. Other concerns include
oreign body implantation, exacerbated by slow resorption,
hat may predispose to empyema formation.11,23,37 Before
he start of this study, 1 patient treated with BioGlue at
horacotomy presented with an empyema 6 weeks postop-
ratively. We cannot be certain whether this complication
as a direct result of using BioGlue, although the possibility
xists. Additional issues include the potential spilling of glue
n large airway stumps preventing efficient stump burial and
redisposing to bronchopleural fistula formation, potential tox-
city, embolic phenomena, and inflammation.38-40
Historically, there has been considerable difficulty in
stablishing a clear message on the effectiveness of surgical
ealants in preventing air leaks.24,27 Indeed, the comment
n the first Cochrane review24 on the need for further ra-
omized, controlled trials initially prompted us to contribute
o the evidence base. For a sealant to be shown to be
ffective, its application should lead to a reduction in the
ncidence and duration of air leak, as demonstrated in this
rial. This prospective, randomized study is the first in
hich the sealant (BioGlue) succeeds in the reduction of air
eak and demonstrates a reduction in drainage time with
ubsequent reduced hospital stay. The study suggests that
he systematic use of BioGlue in the treatment of AAL after
horacotomy may be warranted in adult thoracic surgical
rocedures, with the exception of pneumonectomy and de-
ortication, when an air leak remains after all other steps
o control it have failed. In this context, our study makes
positive contribution to the information available to
urgeons.
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